Enfamil linked to Necrotizing Enterocolitis

For years, Elmiron (pentosan polysulfate sodium) was the only FDA-approved oral medication for interstitial cystitis, a chronic bladder condition. But starting around 2018, mounting evidence linked long-term use of the drug to a distinctive and irreversible form of retinal damage: pigmentary maculopathy. In Illinois, where major medical centers like Northwestern Medicine and the University of Chicago have diagnosed dozens of cases, the legal landscape has shifted dramatically. We are now seeing the first wave of Illinois-specific settlements, and the window for filing a claim is narrowing.

As a firm dedicated to Illinois injury victims, we have tracked every development in the Elmiron multidistrict litigation (MDL No. 2973) and the subsequent state court actions. In 2026, the situation is clear: if you or a loved one took Elmiron for more than two years and now suffer from vision changes—including blurred reading vision, scotomas (blind spots), or difficulty adapting to dim light—you may be entitled to compensation. But the science has evolved, and so have the legal deadlines.

How Elmiron Damages the Retina: The 2026 Clinical Consensus

The link between Elmiron and pigmentary maculopathy is no longer debated. By 2022, studies from Emory University, Kaiser Permanente, and the University of Utah had established a dose-dependent relationship. Patients who accumulated more than 1,500 grams of Elmiron over their lifetime—roughly equivalent to five years of daily use at the standard 300 mg dose—showed a 25% risk of retinal toxicity. In 2026, retina specialists at the Illinois Eye and Ear Infirmary now routinely screen all interstitial cystitis patients with a baseline optical coherence tomography (OCT) before starting Elmiron, and repeat scans annually.

“The retinal pigment epithelium (RPE) accumulates pentosan polysulfate over years, leading to a pattern of hyperpigmentation and atrophy that mimics pattern dystrophy. Once the RPE is damaged, vision loss is permanent. No treatment reverses it.” — Dr. Sarah K. M. Lee, Retina Specialist, University of Illinois Chicago (2025 interview).

For the latest MDL updates and study links, see the Elmiron litigation hub and the archived Illinois settlement page.

In Illinois, the Illinois Department of Public Health issued a 2024 advisory recommending that all Elmiron prescriptions include a written warning about retinal toxicity. Yet many patients who took the drug between 1996 and 2020 were never told. That gap in informed consent is the legal foundation of our claims.

Illinois Statute of Limitations and the 2026 Filing Window

Illinois law gives injury victims two years from the date they discovered—or reasonably should have discovered—that their vision loss was caused by Elmiron. This is critical because many patients were initially misdiagnosed with age-related macular degeneration or pattern dystrophy. In 2026, we are seeing a surge of claims from patients who only learned of the Elmiron link through social media or news reports in 2023 or 2024. For those individuals, the clock started ticking later.

The table above illustrates a hard truth: thousands of Illinois patients who took Elmiron in the 2000s and 2010s may have already lost their right to sue because they knew—or should have known—about the risk before 2024. If you are unsure of your discovery date, we recommend a free consultation to review your medical records and prescription history.

Janssen’s Settlement Strategy and Illinois Court Rulings

Janssen Pharmaceuticals, a subsidiary of Johnson & Johnson, has faced over 3,000 Elmiron lawsuits nationwide. In 2025, the company began offering individual settlement amounts to Illinois plaintiffs with strong documentation—specifically, a confirmed diagnosis of pigmentary maculopathy on OCT or fluorescein angiography, plus proof of at least two years of continuous Elmiron use. The settlement offers have ranged from $75,000 to $450,000 depending on vision loss severity and age.

However, Illinois courts have been particularly tough on plaintiffs who cannot produce pharmacy records. In Doe v. Janssen (Northern District of Illinois, 2025), Judge Sara L. Ellis ruled that a plaintiff’s testimony alone was insufficient to prove cumulative dosage. This means you must locate your prescription bottles, pharmacy printouts, or insurance claims history. We can subpoena these records if needed, but the process takes months.

• Documentation checklist for an Illinois Elmiron claim:
• Pharmacy records showing start and stop dates of Elmiron prescriptions
• Medical records from your urologist confirming interstitial cystitis diagnosis
• OCT or fundus autofluorescence imaging from your ophthalmologist
• A definitive diagnosis of pigmentary maculopathy (not AMD or pattern dystrophy)
• Any correspondence or notes showing you were NOT warned of retinal risks

In 2026, we are also seeing a new trend: Illinois retina specialists are filing mandatory reports with the Illinois Medical Board when they diagnose Elmiron-related maculopathy. These reports are not public, but they can be subpoenaed in litigation. If your doctor filed such a report, it is powerful evidence that your vision loss is linked to the drug.

The bottom line: if you live in Illinois and took Elmiron for interstitial cystitis, do not assume it is too late. Even if your diagnosis was years ago, the discovery rule may still protect you. Contact our office today for a no-cost case evaluation. We handle all Elmiron claims on a contingency basis—you pay nothing unless we recover compensation for you.